ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Amalgam Rx Acquires Adaptive, Conversational, Artificial Intelligence (AI) Assets

Investment Expands Amalgam’s Ability to Deliver Empathetic and Engaging AI-Based Behavioral and Clinical Interventions

Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, is announcing the acquisition of the assets of Geetha, LLC, an adaptive, conversational AI company. The acquisition bolsters Amalgam’s data science assets, which already include more than 6 billion longitudinal data points on millions of patients cared for across Amalgam’s technology platforms.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210520005117/en/

Amalgam Rx Acquires Adaptive, Conversational, Artificial Intelligence (AI) Assets (Graphic: Business Wire)

Amalgam Rx Acquires Adaptive, Conversational, Artificial Intelligence (AI) Assets (Graphic: Business Wire)

Founded in 2014, Geetha boasts a collection of AI models that target the psychosocial and behavioral understanding of stakeholders in the healthcare ecosystem; by establishing learning algorithms to support intervention frameworks, Geetha delivers engaging behavior-change-tailored content using cutting edge Natural Language Understanding and Reinforcement Learning. With this transaction, Amalgam acquires Geetha’s turnkey psychosocial engine (personality, moods, motivators, etc.) in 40 languages, algorithms to collect contextual data via chat, AI-based chat model and platform to create low-no code virtual personalized agents, motivational content, common sense ontology for a rich understanding of a user’s life, and learning algorithms to respond to interactions and improve intervention framework. Geetha’s founder, Bharath Sudharsan, will join the Amalgam executive team as its chief data scientist and head of AI.

“Next-gen AI can deeply understand, empathize, and adapt to each person, almost like a real human friend, with the added benefits of 24/7 availability and expertly curated and safe feedback within a judgment-free space. Every time a patient connects, its rapport, relationship, and level of support can get so much better. When we combine this new AI with Amalgam’s impressive clinical, technology, and regulatory platform/capabilities, it can lead to a deeper level of empathetic engagement, which, in turn can effect lasting change and outcomes,” said Bharath Sudharsan, newly appointed chief data scientist and head of AI of Amalgam Rx.

“The future of digital health is in delivering highly personalized, scalable, and engaging interventions that learn and adapt over time based on an individual's needs; big data and AI form the foundation of this future. We’re thrilled to acquire Geetha’s AI assets and have Bharath join our team,” said Ryan Sysko, chief executive officer and founder of Amalgam Rx.

“Winning digital health solutions of the future will seek to treat the human and not just the patient. Incorporating empathy into patient management is a highly effective and powerful tool to build trust and enhance patient outcomes. It’s an important frontier in the digital health space as emerging AI technologies enable a deeper level of understanding and connection with people,” said Suzanne Clough, MD, chief medical officer of Amalgam Rx.

About Amalgam Rx

Amalgam Rx is the leader in bringing providers, life sciences, and digital solutions together. For more than 15 years, our team has been reimagining care delivery and creating lasting change across the chronic care ecosystem. Working in partnership with many of the world’s leading life sciences companies and health systems, Amalgam Rx has built an innovative platform for rapidly developing and scaling digital solutions — delivered through a wide variety of business models. Our proven end-to-end methodology enables the entire life cycle from R&D to commercialization. Amalgam’s solutions have generated more than 6 billion RWE data points utilized by patients and providers on three continents. For more information on how Amalgam Rx’s regulated, clinically validated technologies bring patients and providers closer together, reduce costs for payers, and unlock sustained value for partners, visit amalgamrx.com.

The future of digital health is in delivering highly personalized, scalable, and engaging interventions that learn and adapt over time based on an individual's needs; big data and AI form the foundation of this future.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  213.21
-5.73 (-2.62%)
AAPL  257.46
-2.83 (-1.09%)
AMD  192.43
-7.02 (-3.52%)
BAC  48.64
-0.89 (-1.80%)
GOOG  298.30
-2.61 (-0.87%)
META  644.86
-15.71 (-2.38%)
MSFT  408.65
-2.03 (-0.49%)
NVDA  177.82
-5.52 (-3.01%)
ORCL  152.96
-1.83 (-1.18%)
TSLA  396.73
-8.82 (-2.17%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.